The rise of GLP-1 weight-loss drugs like Ozempic has led to a phenomenon known as "Ozempic breath," along with side effects like nausea and dry mouth. This has significantly boosted sales of gum and mints, as reported by Hershey's CEO, Kirk Tanner. Hershey is actively researching the increasing use of GLP-1 drugs and its impact on consumer behavior.